Literature DB >> 2429990

Augmentation of fibroblast proliferation by bleomycin.

P L Moseley, C Hemken, G W Hunninghake.   

Abstract

Bleomycin-induced lung disease is characterized by fibroblast proliferation and pulmonary fibrosis. In these studies, we demonstrate that fibroblasts are relatively resistant to clinically relevant amounts (below 10(-4) U/ml) of bleomycin and that these levels of bleomycin augment fibroblast proliferation in response to various fibroblast growth factors. These observations suggest that one mechanism by which bleomycin causes pulmonary fibrosis is augmentation of fibroblast proliferation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429990      PMCID: PMC423797          DOI: 10.1172/JCI112695

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  An 18,000 molecular weight polypeptide induces early events and stimulates DNA synthesis in cultured cells.

Authors:  H R Bourne; E Rozengurt
Journal:  Proc Natl Acad Sci U S A       Date:  1976-12       Impact factor: 11.205

2.  Density-dependent inhibition of fibroblast growth is overcome by pure mitogenic factors.

Authors:  K Mierzejewski; E Rozengurt
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

Review 3.  The platelet-derived growth factor.

Authors:  R Ross; A Vogel
Journal:  Cell       Date:  1978-06       Impact factor: 41.582

4.  Metabolism of vasoactive peptides by human endothelial cells in culture. Angiotensin I converting enzyme (kininase II) and angiotensinase.

Authors:  A R Johnson; E G Erdös
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

5.  Interaction of bleomycin with DNA.

Authors:  M Takeshita; A P Grollman; E Ohtsubo; H Ohtsubo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

6.  Bleomycin lung damage: the pathology and nature of the lesion.

Authors:  A W Jones
Journal:  Br J Dis Chest       Date:  1978-10

7.  Single-strand scission and repair of DNA in mammalian cells by bleomycin.

Authors:  Z M Iqbal; K W Kohn; R A Ewig; A J Fornace
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

8.  The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1974-11       Impact factor: 4.307

9.  Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay.

Authors:  A Broughton; J E Strong; P Y Holoye; C W Bedrossian
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

10.  Lung parenchymal injury induced by bleomycin.

Authors:  P L Moseley; D M Shasby; M Brady; G W Hunninghake
Journal:  Am Rev Respir Dis       Date:  1984-12
View more
  15 in total

1.  Susceptibility of Hermansky-Pudlak mice to bleomycin-induced type II cell apoptosis and fibrosis.

Authors:  Lisa R Young; Rajamouli Pasula; Peter M Gulleman; Gail H Deutsch; Francis X McCormack
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-15       Impact factor: 6.914

2.  Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene.

Authors:  P L Tran; J Weinbach; P Opolon; G Linares-Cruz; J P Reynes; A Grégoire; E Kremer; H Durand; M Perricaudet
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

3.  The effects of bleomycin on alveolar macrophage growth factor secretion.

Authors:  E M Denholm; S H Phan
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

4.  Profibrotic up-regulation of glucose transporter 1 by TGF-β involves activation of MEK and mammalian target of rapamycin complex 2 pathways.

Authors:  Mahefatiana Andrianifahanana; Danielle M Hernandez; Xueqian Yin; Jeong-Han Kang; Mi-Yeon Jung; Youli Wang; Eunhee S Yi; Anja C Roden; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2016-08-01       Impact factor: 5.191

5.  Susceptibility to amiodarone-induced pulmonary toxicity: relationship to the uptake of amiodarone by isolated lung cells.

Authors:  B D Wilson; M L Lippmann
Journal:  Lung       Date:  1996       Impact factor: 2.584

6.  Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Authors:  Craig E Daniels; Mark C Wilkes; Maryanne Edens; Ted J Kottom; Stephen J Murphy; Andrew H Limper; Edward B Leof
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

7.  Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.

Authors:  Mahefatiana Andrianifahanana; Mark C Wilkes; Shiv K Gupta; Rod A Rahimi; Claire E Repellin; Maryanne Edens; Joshua Wittenberger; Xueqian Yin; Elizabeth Maidl; Jackson Becker; Edward B Leof
Journal:  FASEB J       Date:  2013-08-02       Impact factor: 5.191

8.  Cavernous angioma after chemotherapy for desmoplastic/nodular medulloblastoma associated with anhidrotic ectodermal dysplasia.

Authors:  Fumiyuki Yamasaki; Takeshi Takayasu; Ryo Nosaka; Hiroshi Kawaguchi; Kazuhiko Sugiyama; Masao Kobayashi; Kaoru Kurisu
Journal:  Childs Nerv Syst       Date:  2015-08-01       Impact factor: 1.475

Review 9.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

10.  Fatty acid synthase is required for profibrotic TGF-β signaling.

Authors:  Mi-Yeon Jung; Jeong-Han Kang; Danielle M Hernandez; Xueqian Yin; Mahefatiana Andrianifahanana; Youli Wang; Anatilde Gonzalez-Guerrico; Andrew H Limper; Ruth Lupu; Edward B Leof
Journal:  FASEB J       Date:  2018-02-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.